E-cadherin is a cell-cell adhesion molecule that acts as a suppressor of cancer cell invasion and its expression is downregulated in many advanced, poorly differentiated, human cancers. In this study, we found that the expression of DLC1 (deleted in liver cancer 1) tumor-suppressor gene in metastatic prostate carcinoma (PCA) cells increased the expression of E-cadherin and resulted in an elevated rate of cell-cell aggregation as measured by aggregation assay. DLC1-mediated increase in E-cadherin expression was not dependent on a-catenin, a DLC1-binding protein associated with E-cadherin, and/or cellular density. The increase of E-cadherin expression occurred at mRNA level and relied on DLC1 RhoGAP function, leading to suppression of high level of RhoA-GTP and RhoC-GTP activity in metastatic PCA cells. Application of Rho/ROCK inhibitors produced the same effect as introduction of DLC1. Knocking down of RhoA produced a moderate increase in E-cadherin whereas knocking down of RhoC resulted in a significant increase of E-cadherin. Downregulation of E-cadherin caused by constitutively active RhoA V14 and RhoC V14 could not be reversed by expression of DLC1 in DLC1-negative cell line. DLC1-mediated suppression of metastatic PCA cells invasion was comparable with the one associated with ectopic E-cadherin expression, or caused by suppression of Rho pathway either by Rho/ROCK inhibitors, or by shRNA repression. This study demonstrates that DLC1 expression positively regulates E-cadherin and suppresses highly metastatic PCA cell invasion by modulating Rho pathway, which appears as a feasible therapeutic target in cancers with high activity of RhoGTPases.
INTRODUCTION
Deleted in liver cancer 1 (DLC1) is a potent tumor-suppressor gene in several cancers and is increasingly recognized by experts in the field as a metastasis-suppressor gene. [1] [2] [3] [4] [5] DLC1 is a multidomain protein that contains SAM (sterile alpha motif), GAP (GTPaseactivating protein) and START (steroidogenic acute regulatory protein-related lipid transfer) domains. It suppresses proliferation, migration and invasion and induces apoptosis of human liver, breast and prostate cancer cells, 1, 6, 7 by acting mainly as a GAP for RhoA, RhoC and, to lesser extent, for Cdc42. 8 DLC1 is critically involved in the control of Rho signaling and, therefore, affects actin cytoskeletal remodeling and cell-cell contacts. DLC1 protein co localizes and binds with a-catenin 9 and interacts with tensin, talin and focal adhesion kinase, [10] [11] [12] [13] thus influencing molecular machineries of adherens junctions (AJs) and focal adhesions, both of which are highly relevant in cancer cell migration and invasion. High level of RhoGTPases has been implicated in various steps during cellular transformation and tumor cell invasion.
14 During tumor progression, loss of epithelial characteristics involves morphological changes that affect cytoskeletal network, cell-cell adhesion and cell-matrix adhesion. Inappropriate activation of Rho proteins, reported in highly invasive human cancer cells, could be responsible for destabilization of cell-cell contacts and facilitation of invasion.
E-cadherin, on the other side, is a transmembrane protein that is a key component of cell-cell adhesion machinery. It forms a complex with other cytoplasmic proteins like b-catenin, a-catenin and p120 catenin and stabilizes the cell-cell junctions. Cadherins functionally interact with Rac1, RhoA and Cdc42, all of which have role in coupling cytoskeletal structure to cell-cell contacts. 15, 16 Several studies have reported a strong correlation between reduced or lost expression of E-cadherin and tumor progression; E-cadherin downregulation is generally a result of transcriptional repression, [17] [18] [19] post-translational processing 20, 21 or its endocytosis. 22 A direct role of E-cadherin expression in suppression of invasive phenotype was explored in transgenic mouse model of pancreatic b-cell carcinogenesis, 23 and was shown that loss of E-cadherin facilitated a transition from welldifferentiated adenoma to carcinoma and, in the case of forced expression of a truncated dominant negative gene, increased incidence of carcinomas and of metastasis. Conversely, reintroduction of E-cadherin expression resulted in significant reduction in frequency of carcinomas vs well-differentiated adenomas, thus indicating that the loss of E-cadherin-mediated cell adhesion is required for invasion in vivo. Recently, it was reported that E-cadherin-mediated suppression of anchorageindependent growth and cell migration is associated with reduced activity of RhoA or cdc42, apparently consequential to DLC1 and p190RhoGAP action. 24 In this study, we show that DLC1expression increases the expression of E-cadherin and, consequently, abrogate the invasiveness of a highly malignant prostate carcinoma (PCA) cell line. The DLC1-mediated process apparently results from its RhoGAP action; attenuation of Rho proteins activity by specific Rho/Rock inhibitors, or intervention with shRNA, restores E-cadherin expression. Expression and localization of E-cadherin, disrupted by constitutively active, GTP-bound, RhoA V14 and RhoC V14 , shown to be resistant to GAP action, is not reversed by DLC1 expression. Reduction in invasiveness of highly malignant PCA cells mimics the one observed in cases of E-cadherin overexpression or downregulation of Rho activity.
RESULTS
DLC1 increases expression of E-cadherin in cancer cells and elevates the rate of cell-cell aggregation Androgen independent and metastatic prostate cancer cells C4-2-B2 and PC-3 express lower levels of E-cadherin as compared with RWPE-1, a normal immortalized prostate epithelial cell (Figure 1a) . Transduction of DLC1 in these cells and its expression to the physiological levels was associated with noticeable increase in the expression of E-cadherin as shown by western blot and immunofluorescence staining (Figures 1a and b) . To examine the effects of DLC1-mediated increased expression of E-cadherin on cell aggregation ability in vitro, Ad-LacZ-and DLC1-transduced C4-2-B2 and PC-3 cells were cultured, and their aggregation index was measured at 0 and 60 min in a calcium-containing buffer (2 mM Ca 2 þ ). At the 60-min endpoint, DLC1-transduced cells with increased levels of E-cadherin expression showed increased aggregation compared with their control counterparts ( Figures  1c and d) . Treatment with either anti-E-cadherin antibody (HEDC-1) or with calcium chelating agent EGTA (ethylene glycol tetraacetic acid), both used to disrupt E-cadherin activity, abolished DLC1/E-cadherin-induced aggregation (Figure 1d ). DLC1-mediated increase in E-cadherin expression is independent of a-catenin and culture density, but E-cadherin localization is dependent on a-catenin Alpha-catenin acts as a molecular link between DLC1 and E-cadherin. To check whether DLC-mediated increase in E-cadherin expression was dependent on a-catenin, shRNA was used to knock down a-catenin in C4-2-B2 cells, and stable clone exhibiting maximum effect was selected for the study. 9 Transduction of these cells with DLC1 resulted in increased expression of E-cadherin compared with controls and proved that such increase was independent of a-catenin (Figure 2a ). Yet, as shown by Immunofluorescence analysis, localization of E-cadherin at AJs required both DLC1 and a-catenin (Figure 2b ). This observation was confirmed in PC-3 cells negative for both DLC1 and a-catenin (Figures 2a and c) . To examine whether culture density affects DLC1-mediated increase in E-cadherin expression, DLC1-positive and -negative C4-2-B2 cells were grown for 2 days in sparse ( (Figure 2d ). Densitometric analysis showed that transduction with DLC1 caused approximately twofold increase in E-cadherin expression compared with transduction with LacZ irrespective of culture density (Figure 2d ). Differential partitioning of cell membranes into TritonX-100-soluble and insoluble fractions and their subsequent probing for E-cadherin confirmed irrelevance of cell density and showed that DLC1-mediated increase in E-cadherin expression was confined to insoluble skeletal fraction of membranes (Figure 2e ).
DLC1 increases E-cadherin expression in a GAP-dependent manner at transcriptional level To determine whether DLC1 RhoGAP activity is required for the restoration of E-cadherin expression, C4-2-B2 and PC-3 cells were transduced with V5-tagged full-length DLC1 and stably DLC1 modulates E-cadherin and suppresses invasion V Tripathi et al transfected with DLC1 GAP mutant (R718E) or DLC1 GAP-deleted construct (1-630), and E-cadherin expression was examined by western blot and immunofluorescence (Figures 3a and b) . Because E-cadherin expression was positively affected only by the fulllength DLC1 but not by either GAP mutant or the GAP-deleted construct, the experiment confirmed that GAP domain is required for DLC1-mediated E-cadherin expression. Real-time PCR analysis of C4-2-B2 and PC-3 cells transduced and/or transfected with LacZ, DLC1 and DLC1R718E showed that DLC1-mediated increase in E-cadherin occurred at the mRNA level ( Figure 3c ). Only full-length DLC1 was able induce E-cadherin expression, whereas DLC1GAP-dead R718E was ineffective ( Figure 3c ).
DLC1 suppresses RhoA and RhoC activation and requires E-cadherin for optimum suppression Introduction of DLC1 in DLC1-negative cells not only increases the expression of E-cadherin but also suppresses both RhoA and RhoC expression (Figures 4a and b) . The comparison between two PCA cell lines (PC-3 and C4-2-B2) and one normal prostate immortalized cell line (RWPE-1) revealed that in cancer cells expression of both RhoA and RhoC was significantly higher than in normal immortal one ( Figure 4c ). Interestingly, the expression of E-cadherin was inversely correlated to expression of Rho proteins; it was high in RWPE-1 and significantly lower in C4-2-B2 and PC-3 as confirmed by both blotting ( Figure 4c ) and immunofluorescent detection (Figure 4d ). To understand the relation between DLC1, E-cadherin and Rho proteins, E-cadherin was stably knocked down in C4-2-B2 cells (Figure 4e ), and stable clone (D3) was then transduced with either Ad-Lac Z or DLC1 and examined for RhoA and RhoC activity (Figures 4f and g ).
In the absence of E-cadherin, the efficiency of DLC1-mediated suppression of RhoA and RhoC was markedly reduced, thus indicating that E-cadherin is required for effective inhibition of those two proteins by DLC1.
Rho/ROCK inhibitors affect E-cadherin expression similar to DLC1 To gain insights into the molecular mechanisms underlying DLC1-mediated increase in E-cadherin expression, C4-2-B2 cells were treated with Rho inhibitor C-3 or ROCK inhibitor Y-27632 ( Figure 4h ). As expected, Y-27632 showed no effect in suppressing Rho, whereas C3 reduced RhoA and RhoC activity as much as DLC1 did. A similar, but reversed, pattern was observed with E-cadherin expression (Figure 4i ), which appears to have been equally increased with either introduction of DLC1 or by application of Rho or ROCK inhibitors. Immunofluorescent labeling (Figure 4j ) confirmed the boost in E-cadherin expression. Effects of Rho or ROCK inhibitors' phenocopied the effect caused by introduction of DLC1.
DLC1 restores the Rho protein-mediated disruption of AJs
To differentiate the roles of RhoA and RhoC in DLC1-mediated increase of E-cadherin expression, different shRNA plasmids were tested for their ability to effectively suppress the expression of either of them (Figure 5a ). Stable clones with maximum knock down of RhoA (D2) and RhoC (D3) were selected, and E-cadherin expression was analyzed in the presence or absence of DLC1. The reduction in each respective Rho's expression positively correlated with suppression of its activity (Figure 5b ). Analysis showed that inhibition of RhoC had more profound effect on E-cadherin expression than the inhibition of RhoA, as use of shRhoC resulted in E-cadherin's increase comparable with that caused by DLC1 alone (Figures 5c and d) . Additional transduction of shRhoA-or shRhoC-transfected cells with Ad-DLC1 leveled the field by showing somewhat stronger effect in case of shRhoA-transfected cells, thus raising the possibility that active RhoC may have stronger role in suppressing E-cadherin expression and that DLC1 restores E-cadherin by negatively modulating RhoC activity more than that of RhoA. Transfection of C4-2-B2 cells with myc-tagged constitutively active RhoA V14 and RhoC V14 , refractory to DLC1 action, showed significant reduction in E-cadherin presence on membranes of cells containing the respective Rho transgene(s) and, particularly, disruption of E-cadherin at AJs (Figure 6a) . Although DLC1 was able to increase the expression of E-cadherin in all Rho transgenenegative, it was not able to correct the expression and localization of E-cadherin in RhoA V14 -or RhoC DLC1 modulates E-cadherin and suppresses invasion V Tripathi et al and compared for their invasion competence. Introduction of DLC1 or activation of E-cadherin expression equally repressed invasion; conversely, suppression of E-cadherin or absence of DLC1 both resulted in significantly increased invasion capacity (Figures 6b and d) . Suppression of RhoA or RhoC by their corresponding shRNAs reduced invasion as well, but the effects was significantly more pronounced when RhoC was suppressed than RhoA, thus confirming an earlier observation on their respective roles in E-cadherin induction. Use of Rho inhibitor C3 and of ROCK inhibitor Y27632 also significantly reduced invasion capacity of C4-2-B2 cells, and the extent of suppression mimicked the one caused by RhoC shRNA (Figure 6c ). Expression of DLC1 or suppression of RhoC produced comparable attenuation of invasion, strongly indicating that DLC1 RhoGAP activity is inducing E-cadherin expression by acting mostly through RhoC and that such action is responsible for suppression of invasion of C4-2-B2 cells.
DISCUSSION
The crucial step in progression of tumor cell toward a more aggressive phenotype depends on deregulation of cytoskeleton structure and adhesion machinery, which allows separation of individual cells from the bulk of tumor and, consequently, their invasion of surrounding tissues and/or distant sites. Such separation is frequently associated with local depletion of E-cadherin, whose extracellular domains at the surface of adjacent cells interact with one another, while their cytoplasmatic domains connect to the respective cell's actin cytoskeletons via catenins. In this study, we report that expression of DLC1, a tumor- DLC1 modulates E-cadherin and suppresses invasion V Tripathi et al suppressor gene, induces E-cadherin expression in androgenindependent and metastatic PCA cells and that such an effect is independent of a-catenin and/or of cell culture density. Downregulation of E-cadherin in these cells coincided with high level of expression of active Rho proteins. As either expression of DLC1 or attenuation of RhoA and RhoC by other means-chemical inhibitors or shRNAs-both resulted in restored E-cadherin expression, mechanism of DLC1 action was clearly attributable to this protein's RhoGAP domain and function. DLC1-mediated increase in E-cadherin reduced invasion capacity of metastatic PCA cells and suppressed their invasion in vitro. Metastatic PCA cell lines C4-2-B2 and PC-3 chosen for this study have been extensively examined and well characterized in our laboratory. 7, 25 They both are deficient in DLC1 expression due to either promoter hypermethylation (C4-2-B2) or genomic deletion (PC-3). DLC1 transduction in these cells suppresses tumorigenicity, invasion and proliferation. In addition, both the cell lines express lower level of E-cadherin, as compared with the normal prostate epithelial cell, which makes them a suitable model for exploring the interactions of those two proteins.
The fact that DLC1-mediated E-cadherin expression affected invasion is not surprising because the role of E-cadherin as a repressor of metastasis is well established. 26, 27 Migration and invasion of tumor cells are also promoted by the loss of interaction between cytoskeleton and AJs, whose major component is E-cadherin, subsequent to changes in the activities of Rho family small GTPases and the concomitant reorganization of the actin cytoskeleton. 14, 28 On the other side, matrix metalloproteinase (MMP) molecules MMP-7 and MMP-13 were shown to cleave cell surface E-cadherin, thus forming a soluble ectodomain of E-cadherin, which has paracrine effect and inhibits E-cadherin function. 29 The loss or downregulation of E-cadherin expression in epithelial cells leads to abrogation of cell-cell contacts and increased motility, whereas forced expression of E-cadherin protein in metastatic tumor cells is sufficient for reversal of metastatic phenotype. 23, 30 Even cytoplasmic expression of E-cadherin was shown as sufficient to suppress invasion of MDA-MB-231 breast cancer cells and TSU-Pr1 prostate cancer cells. 31 Immunohistochemical studies demonstrated that aggressive PCA exhibits decreased or otherwise abnormal expression of E-cadherin. 21, 32, 33 In a majority of human cancers, E-cadherin remains genetically intact but is frequently silenced by transcriptional and translational mechanisms during the progression to invasive phenotype. Repression of E-cadherin transcripts via E-box-binding proteins (for example, Snail and Slug) has been described in detail and is also associated with tumor metastasis. In that context, culture density appears to affect the E-cadherin expression due to transcriptional repression of E-cadherin in sparse cultures by activated extracellular signal-regulated kinase-or b-cateninsignaling through transcription factor Slug. 34 Our results obtained on sparse, intermediate and confluent cell cultures rule out the possibility that transcriptional repression by Slug-on the E-box element in E-cadherin promoter-is the mechanism underlying the E-cadherin variations in this study.
They, however, clearly point to GAP function of DLC1 molecule in triggering signaling cascade leading to E-cadherin re-expression in C4-2-B2 and PC-3 cells. Real-time PCR data revealed that DLC1-mediated expression occurred at mRNA level. Knocking down of RhoA and RhoC lowered the levels of active RhoA and 
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RhoC and restored the E-cadherin expression; however, the effect was more pronounced when RhoC was suppressed and appeared to be similar, if not the same, as the effect of DLC1 introduction. The Rho family of small GTPases, particularly subclasses Rho, Rac and cdc42, have been increasingly recognized as key players in regulation of AJs, due to their effect on the actin cytoskeleton. 15, [35] [36] [37] Rho proteins can be activated by guanine nucleotide exchange factor or inactivated by GTPase-activating protein (GAP). Unlike Ras, there are no reports of mutated, constitutively active forms of Rho proteins in tumors. Small GTPases from Rho family affect complex cellular processes with repercussions on cytoskeletal dynamics, cell-cycle progression and cancer cell migration 38 and augment prostate cancer cell invasion. 39 Among them, RhoA and RhoC are of particular interest because RhoA expression correlate positively with the progression of breast cancer and testicular germ-cell tumors, 40 disrupts AJs through cyclooxygenase-2 signaling and increases cell motility in colorectal cancer. 41 On the other side, RhoC is overexpressed in pancreatic DLC1 modulates E-cadherin and suppresses invasion V Tripathi et al ductal adenocarcinoma and inflammatory breast cancer [42] [43] [44] and its inactivation leads to morphological changes in PCA cell lines. 45 RhoA and RhoC role in DLC1-mediated E-cadherin induction was further clarified by using constitutively active RhoA and RhoC, whose action was not reversible by DLC1.
Our invasion data showed that DLC1 suppressed invasion potential of C4-2-B2 cells to the same extent as ectopic expression of E-cadherin, or inhibition of Rho/ROCK pathway by pharmacological inhibitors or by shRNA knockdown. A ROCK pathway is one of the two pathways downstream of Rho with effect on AJs; Dia1 stabilizes them, whereas ROCK disrupts cell-cell junctions through the generation of actin contractile force.
46 DLC1-mediated suppression of ROCK has been shown to negatively affect cell migration 47 and Rho/ROCK pathway has been strongly implicated in ovarian and bladder cancer cell migration and invasion. 48, 49 Pretreatment of cells with a pharmacological inhibitor of Rho/ROCK (Y-27632) or overexpression of dominant negative mutant of Rho N19 effectively inhibited invasion potential of ovarian cancer cells. 50 As ROCK is more efficient substrate of RhoC, RhoC/ROCK could be the major pathway affecting E-cadherin in cell lines overexpressing RhoC. Our finding that ROCK inhibitor is effective in restoring E-cadherin is, therefore, plausible in the context of the above-mentioned results.
Seemingly, restoration of E-cadherin function may have therapeutic implications in certain cases. 51, 52 For example, gamma-linolenic acidhas been used to modulate E-cadherin expression in several tumor cell lines. 53 In addition, the treatment of breast tumor cells in 3-D culture with a -integrin antibody triggered increased E-cadherin expression 54 and caused a reversion of the malignant phenotype. A combined treatment with PPARg (peroxisome proliferator-activated receptor-g) agonist and histone deacetylase inhibitor highly upregulated E-cadherin and impaired the bone invasive potential of prostate cancer cells in mice. 55 Our data categorize DLC1 as an additional upregulatory factor of E-cadherin. Our study provides no evidences for transcriptional or translational modification of E-cadherin and demonstrates the DLC1's GAP ability to modulate activity of small Rho GTPases, upregulate E-cadherin, affect cell-cell adhesion and, consequently, migration and invasion. As previously discussed, 56, 57 this study also strengthens the view of ROCK inhibitors as a promising anticancer agent.
MATERIALS AND METHODS
Cell lines and culture conditions PC-3 and RWPE-1 cells lines were purchased from American Type Culture Collection (Rockville, MD, USA). PC-3 was cultured in RPMI 1640 medium (Invitrogen, San Diego, CA, USA) supplemented with heat inactivated 10% fetal bovine serum. RWPE-1 was cultured in keratinocyte medium (Invitrogen) supplemented with epithelial growth factor (Invitrogen) and bovine pituitary extract (Invitrogen). C4-2-B2 cell line was purchased from ViroMed, Lab Inc. (Minneapolis, MN, USA) and was cultured in T-medium (Invitrogen) supplemented with 10% fetal bovine serum. All cell cultures were grown in a humidified CO 2 incubator at 37 1C.
Plasmids, transfections and real-time PCR
For stable silencing of a-catenin, RhoA, RhoC, and E-cadherin, four respective SureSilencing shRNA plasmid vectors (KH00305H, KH01089N, KH00135P, SABiosciences, Frederick, MD, USA), containing different resistance gene, were transfected into cells using lipofectamine 2000, and the media containing antibiotic was changed after 48 h. Two weeks post transfection, single colonies were picked up and expanded. An adenovirus encoding either DLC1 cDNA or LacZ was prepared and transduced as previously described. 7 Adenovirus encoding a-catenin was purchased from Vector Biolabs (Philadelphia, PA, USA). Myc tagged RhoA V14 and RhoC V14 were a kind gift from Christopher J Marshal (Cancer Research UK Center for Cell and Molecular Biology). For real-time PCR, RNA was prepared using RNAesy mini kit (Qiagen, Valencia, CA, USA) and cDNA were prepared using SuperScript III First-Strand Synthesis SuperMix for quantitative reverse transcriptase-PCR (Invitrogen). Quantitative PCR for E-cadherin (Hs00170423_a1CDH1) was performed using Taqman Gene Expression Assays (Applied Biosystem, Carlsbad, CA, USA).
Western blotting
Cells were lysed with NP-40 lysis buffer (BioSource, Camarillo, CA, USA) supplemented with Protease Inhibitor Cocktail (Sigma, St Louis, MO, USA). Centrifugation was done at 12 000 g for 20 min at 4 1C. Supernatant was collected and protein level determined by BCA protein assay (Thermo Scientific, Rockford, IL, USA). Lysate was loaded on 4-12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gels (Invitrogen), transferred to nitrocellulose membranes (Invitrogen). Antibodies used for western blot were: monoclonal anti-a-catenin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), monoclonal anti-DLC1 antibody (BD Biosciences, San Jose, CA, USA), anti-E-cadherin, anti-RhoA and antiRhoC antibody (Abcam, Cambridge, MA, USA).
Preparation of Triton X-soluble and insoluble membrane fractions Cells were harvested, lysed in NP-40 lysis buffer (BioSource, Camarillo, CA, USA) and supplemented with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). Lysate was ultracentrifuged at 100 000 g, for 30 min at 4 1C to pellet membrane fraction, which was then dissolved in phosphatebuffered saline containing 0.5% Triton X-100 and centrifuged for 20 min at 12 000 g at 4 1C. Supernatant was collected as Triton X-100-soluble fraction, whereas the pellet was dissolved in phosphate-buffered saline with 1% SDS and collected as Triton X-100-insoluble fraction.
Rhotekin assay C4-2-B2 cells were grown to confluence and Rhotekin assay was used according to manufacturer's (Cell Biolabs, San Diego, CA, USA) instruction. Briefly, Cells were lysed on ice for 10 mins in 1 Â lysis buffer supplemented with protease inhibitors cocktail (Sigma-Aldrich) and 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), and the lysate was centrifuged at 13 000 g and 4 1C for 5 min. Small aliquot of lysate was analyzed for total protein content and total RhoA or RhoC content. The remainders of the cell lysates were used for the Rho activation assay (Cell Biolabs). Rhotekin beads were incubated with cell lysates for 4 h and washed thoroughly five times in washing buffer before active Rho proteins attached to beads were separated by SDS-PAGE in 4-12% acrylamide gels. RhoA and RhoC were detected with anti-Rho primary antibodies (Abcam).
Immunofluorescence analysis
Cells were grown on chamber slides, fixed with 4.0% paraformaldehyde for 20 min and permeabilization was performed in 0.5% Triton-X for 5 min. After blocking in 3% bovine serum albumin, the slides were incubated overnight with primary antibodies at 4 1C. The following primary antibodies were used for detection: goat polyclonal anti-DLC1, mouse monoclonal anti-E cadherin, and anti-a-catenin, (Santa Cruz Biotechnology). Secondary antibodies used were anti-mouse Alexa Fluor 488, antigoat Alexa Fluor 568 and anti-mouse Alexa Fluor 650 (Molecular Probe, Carlsbad, CA, USA). Confocal imaging was performed with a Zeiss LSM 510 NLO confocal system (Carl Zeiss Inc., Thornwood, NY, USA) based on a Axiovert 200 M inverted microscope and operating with a 30-mW argon laser tuned to 488 nm, a 1-mW HeNe laser tuned to 543 nm and a 1-mW HeNe laser tuned to 633 nm. Images were collected in Zeiss AIM software (v 4.0) using a Â 63 or Â 40 Plan-Apochromat 1.4 NA oil immersion objective and a multi-track configuration where different color signals were sequentially collected in separate photomultiplier tubes with a BP 500-530 nm, BP 565-615 nm and BP 650-710 filters after excitation with 488 nm, 543 and 633 nm laser, respectively. Images were 512 Â 512 pixels with line having average 4.
Invasion assay
Cell invasion assays were performed using 8-mm pore size BD FalconFluoroBlok (Becton Dickinson, Franklin Lakes, NJ, USA). Cells were transduced with Ad-DLC1 or Ad-LacZ or stably transfected with ShRNA of E-cadherin and GFP-E-cadherin, and 1 Â 10 6 cells/well were plated on ECMatrix gel-coated layered cell culture inserts. After 24 h, the noninvading cells and the extracellular Matrix gel from the interior of the inserts were removed using a cotton-tipped swab. Invaded cells were stained or quantitated using calcein AM fluorescent dye (Becton DLC1 modulates E-cadherin and suppresses invasion V Tripathi et al Dickinson), and fluorescence was measured at wavelength 494/517 (absorbance/emission).
Cell aggregation assay
Cells were transduced with Ad-LacZ or Ad-DLC1 in medium with 10% fetal bovine serum. To dissociate cells, a solution 0.05% Trypsin in phosphatebuffered saline with calcium was added, cells were collected and washed with balanced salt solution containing 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Cells were dissolved in HBSS (Hank's Balanced Salt Solution) buffer containing 0.01% trypsin and 10 mM HEPES for 30 min at 37 1C to have single-cell suspension followed by washing. Further, cells were resuspended in HBSS (with 10 mM HEPES) and concentration was adjusted to 1 Â 10 5 cells/ml. They were then added into a 24-well tissue culture plate and placed on a shaker at 60 r.p.m. and incubated at various time points. In selected cultures, HECD-1 (Abcam) or EGTA was included. Proportions of this cell suspension were removed at 15, 30 and 45 min and placed in ice and then fixed in a one volume of 5% paraformaldehyde. Total numbers of particles were counted, and the aggregation index was calculated using formula N0 À Nt/N0, where N0 is the number of particles at zero time, that is, just when the experiment started, and Nt is the number at the particular time.
